Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $22.91 in the prior trading day, Immunovant Inc (NASDAQ: IMVT) closed at $22.84, down -0.31%. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 0.83 million shares were traded. IMVT stock price reached its highest trading level at $23.12 during the session, while it also had its lowest trading level at $22.58.
Ratios:
Our goal is to gain a better understanding of IMVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.07 and its Current Ratio is at 9.07. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On March 03, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $20.Jefferies initiated its Hold rating on March 03, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Fromkin Andrew J. sold 22,249 shares for $23.25 per share. The transaction valued at 517,189 led to the insider holds 85,852 shares of the business.
Hughes Douglas J. sold 15,000 shares of IMVT for $348,665 on Dec 01 ’25. The Director now owns 120,773 shares after completing the transaction at $23.24 per share. On Dec 01 ’25, another insider, ANDREW J FROMKIN, who serves as the Director of the company, bought 22,249 shares for $24.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 4003315968 and an Enterprise Value of 3481445888.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.58, which has changed by -0.2041812 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $29.49, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is 9.95%, while the 200-Day Moving Average is calculated to be 31.03%.
Shares Statistics:
The stock has traded on average 1.72M shares per day over the past 3-months and 1234610 shares per day over the last 10 days, according to various share statistics. A total of 174.53M shares are outstanding, with a floating share count of 74.15M. Insiders hold about 57.70% of the company’s shares, while institutions hold 54.83% stake in the company. Shares short for IMVT as of 1763078400 were 16381611 with a Short Ratio of 9.53, compared to 1760486400 on 17009989. Therefore, it implies a Short% of Shares Outstanding of 16381611 and a Short% of Float of 26.97.
Earnings Estimates
. The current rating of Immunovant Inc (IMVT) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.57 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.54 and -$3.34 for the fiscal current year, implying an average EPS of -$2.97. EPS for the following year is -$3.0, with 11.0 analysts recommending between -$1.96 and -$3.98.
